Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of effectiveness of tocilizumab in treating rheumatoid arthritis patients with high versus low comorbidity burden and in obese versus nonobese: The US Corrona RA registry study

Trial Profile

Comparison of effectiveness of tocilizumab in treating rheumatoid arthritis patients with high versus low comorbidity burden and in obese versus nonobese: The US Corrona RA registry study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary) ; Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Oct 2018 Results assessing the effectiveness of tocilizumab in treating rheumatoid arthritis patients with high vs low comorbidity burden (n=770) and in obese vs nonobese patients (n=805), presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 17 Jul 2018 New trial record
    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top